<DOC>
	<DOCNO>NCT00398138</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide may help body build effective immune response kill cancer cell . Biological therapy , GM-CSF , may stimulate immune system different way stop cancer cell grow . Giving vaccine therapy together GM-CSF may kill cancer cell . PURPOSE : This phase I trial study side effect vaccine therapy GM-CSF treat patient acute myeloid leukemia , myelodysplastic syndrome , non-small cell lung cancer , mesothelioma .</brief_summary>
	<brief_title>Vaccine Therapy GM-CSF Treating Patients With Acute Myeloid Leukemia , Myelodysplastic Syndromes , Non-Small Cell Lung Cancer , Mesothelioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety immunogenicity Wilms tumor-1 analog peptide vaccine patient acute myeloid leukemia , myelodysplastic syndrome , non-small cell lung cancer , mesothelioma . Secondary - Determine antitumor effect vaccine patient . OUTLINE : This pilot study . Patients stratify accord disease type ( acute myeloid leukemia [ AML ] myelodysplastic syndrome [ MDS ] v non-small cell lung cancer mesothelioma ) . Patients receive vaccine comprise Wilms-tumor 1 ( WT-1 ) analog peptide emulsify Montanide ISA-51 subcutaneously ( SC ) week 0 , 4 , 6 , 8 , 10 , 12 sargramostim ( GM-CSF ) SC twice week 0 , 4 , 6 , 8 , 10 , 12 ( day 2 day prior vaccination ) . Patients immunologic response disease progression may receive 6 vaccination approximately 1 month apart . Blood sample collect baseline , week 8 , week 14 . Samples examine polymerase chain reaction ( PCR ) measure level WT-1 T-cell proliferative response , delayed-type hypersensitivity WT-1 peptide , ELISPOT measure immune response . Bone marrow sample collect patient AML MDS baseline week 14 . Samples examine PCR measure level WT-1 multiparameter flow cytometry measure residual disease .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically histologically confirm diagnosis 1 following : Acute myeloid leukemia , meet follow criterion : Documented Wilms tumor1 ( WT1 ) positive disease demonstrate WT1 protein pretreatment bone marrow biopsy OR detectable disease realtime quantitative reverse transcriptasepolymerase chain reaction ( RQPCR ) Completed induction chemotherapy , achieve clinical remission , complete postremission therapy OR achieve clinical remission plan postremission chemotherapy ( ≥ 65 year age ) Myelodysplastic syndrome , meet follow criterion : Documented WT1positive disease demonstrate WT1 protein pretreatment bone marrow biopsy OR detectable disease RQPCR International Prognostic Scoring System ( IPSS ) score ≥ Int2 Not candidate cytotoxic chemotherapy Nonsmall cell lung cancer , meet follow criterion : Positive tumor stain WT1 &gt; 10 % cell Stage III IV disease Completed chemotherapy , surgery , and/or radiotherapy Mesothelioma , meet follow criterion : Positive tumor stain WT1 &gt; 10 % cell Unresectable relapsed disease Chemonaive receive 1 prior chemotherapy regimen Malignant pleural mesothelioma peritoneal mesothelioma No leptomeningeal disease No CNS involvement PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Absolute neutrophil count ≥ 1,000/mm³ Platelet count &gt; 50,000/mm³ ( except myelodysplastic syndrome parameter &gt; 20,000/mm³ transfusion dependent ) Bilirubin ≤ 2.0 mg/dL AST ALT ≤ 2.5 time upper limit normal Creatinine ≤ 2.0 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection require systemic antibiotic , antiviral , antifungal treatment No serious unstable medical illness PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 week since prior chemotherapy radiotherapy No concurrent systemic corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>